权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chemical Exchange Weighted Molecular MRI: Technical Development and Clinical Translation

化学交换加权分子 MRI：技术开发和临床转化

基本信息

批准号：
10669227
负责人：
Ravinder Reddy
金额：
$ 20.32万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-20 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10669227
关键词：
3-Dimensional Address Alzheimer&apos s disease model Animal Model Biological Markers Blood Brain Brain imaging Breathing Cardiac Central Nervous System Diseases Chemical Models Chemicals Clinical Collaborations Consumption Country Creatine Dependence Development Diagnosis Disease Disease Progression Doctor of Philosophy Early Diagnosis Epilepsy Exercise Glutamates Goals Heart Human Human Activities Image Imaging Techniques Institution Kinetics Machine Learning Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Maps Measurement Measures Mediating Metabolic Metabolic Pathway Metabolism Methods Mitochondrial Diseases Modeling Molecular Monitor Myocardium Neurotransmitters Oxidative Phosphorylation Parkinson Disease Pathogenesis Patient Care Patients Physicians Play Positron-Emission Tomography Process Protons Radioisotopes Recovery Research Personnel Resolution Sampling Scanning Scheme Schizophrenia Scientist Services Signal Transduction Skeletal Muscle Slice Specificity System Techniques Technology Testing Time Training Translations Treatment Efficacy absorption biomedical scientist brain tissue clinical translation commercialization data analysis pipeline data exchange deep learning healthy volunteer heart motion high resolution imaging human subject improved in vivo learning strategy metabolic imaging molecular imaging myoinositol neurochemistry new technology next generation novel novel therapeutics precision medicine radio frequency simulation spatiotemporal therapeutic development therapeutic evaluation treatment response

项目摘要

TR&D1: Chemical Exchange Weighted Molecular MRI: Technical Development and Clinical Translation Project PI: Ravinder Reddy, PhD Abstract This TR&D project focuses on metabolite weighted CEST MRI technologies for spatially resolved imaging of several key metabolites (glutamate, myoinositol, creatine and lactate) that serve as biomarkers of a variety of disease processes. To this end, it develops novel technologies including (i) deep learning approaches for B1 and B0 correction of CEST images of different metabolites (ii) volumetric acquisition methods for improved spatial resolution of the CEST weighted imaging of different metabolites and (iii) technologies for dynamic studies of exercise mediated OXPHOS measurements in skeletal muscle, and (iv) CrCEST acquisition methods for measuring the metabolic activity of human myocardium. These technologies are driven by 7 collaborations and serve 8 service projects from within PENN and from other institutions distributed across the US. Successful completion of the goals will lead to technologies that will have sustained impact on the field of biomedicine through their contribution to the understanding of pathophysiological underpinnings of several disorders, and through the use of these technologies as biomarkers for diagnosis and evaluation of therapeutic responses of existing and novel therapies that constitute precision medicine strategies for patient care. In addition, dissemination of these technologies to collaborators from PENN and institutions across the country and abroad, and training of next generation of biomedical scientist and physician scientists, and potential opportunities for commercialization of the technologies will have immense national impact.

TR&D1：化学交换加权分子 MRI：技术开发和临床转化项目负责人：Ravinder Reddy 博士抽象的该 TR&D 项目重点关注代谢物加权 CEST MRI 技术，用于空间分辨成像几种关键代谢物（谷氨酸、肌醇、肌酸和乳酸）可作为多种代谢物的生物标志物疾病过程。为此，它开发了新技术，包括 (i) B1 和不同代谢物的 CEST 图像的 B0 校正 (ii) 改进空间的体积采集方法不同代谢物的 CEST 加权成像分辨率和 (iii) 动态研究技术运动介导的骨骼肌 OXPHOS 测量，以及 (iv) CrCEST 采集方法测量人体心肌的代谢活动。这些技术是由 7 项合作推动的为 PENN 内部和分布在美国各地的其他机构的 8 个服务项目提供服务。成功的目标的完成将带来对生物医学领域产生持续影响的技术通过他们对理解几种疾病的病理生理学基础的贡献，以及通过使用这些技术作为诊断和评估治疗反应的生物标志物现有的和新颖的疗法构成了患者护理的精准医学策略。此外，将这些技术传播给 PENN 和国内外机构的合作者，下一代生物医学科学家和医师科学家的培训，以及潜在的机会这些技术的商业化将对国家产生巨大影响。